Navigation Links
Ikaria Founding Scientist Named 2007 MacArthur Fellow

CLINTON, N.J., Sept. 26 /PRNewswire-USNewswire/ -- Mark Roth, Ph.D., an advisor and founding scientist of Ikaria, this week received a MacArthur Fellowship award, which includes a grant to further his research over the next five years.

Roth, a member of the Fred Hutchinson Cancer Research Center's Basic Sciences Division, received five years of "no-strings-attached" support from the John D. and Catherine T. MacArthur Foundation for his pioneering research in basic biology. Most notably, his research has pioneered reversible metabolic hibernation -- a finding that may have clinical benefits in humans.

"Mark is an extraordinarily talented scientist, as well as a great friend and colleague to the Ikaria team," said Ikaria Chairman and CEO David Shaw. "We are very pleased that the MacArthur Foundation recognized the importance of Mark's groundbreaking research through this prestigious award. We look forward to making the benefits of this research available to patients in the future."

In April 2005, Roth demonstrated the ability of the biological gas hydrogen sulfide to induce a state of reversible metabolic hibernation in mice, which may be a latent ability in all mammals. Temporary slowing of the metabolic rate, or inducing hibernation on demand, has the potential to lengthen the window of time that patients with trauma, stroke, cardiac arrest or surgery can be treated. In addition to increasing the time that transplant organs or tissues are viable outside the body, this expanded time window could help prevent injury and death from insufficient or inappropriate oxygen supply to organs and tissues.

Ikaria has submitted regulatory documents for hydrogen sulfide as an experimental drug. The company is expected to start a Phase I trial later this year.

The MacArthur Fellowship Program recognizes talented individuals who have shown exceptional originality and dedication in their creative pursuits. Its purpose is to invest in a person's "originality, insight, and potential," enabling recipients to exercise their own creative instincts for the benefit of human society. Since its start in 1981, the program has named 756 Fellows, including Roth, who was among the 24 recipients announced this week.

About Ikaria Holdings

Ikaria Holdings is a fully integrated biotherapeutics company focused on the development and commercialization of innovative in-hospital pharmaceutical products and drug/device combinations that improve the lives of patients. The company's INOmax(R) product (inhaled nitric oxide) is an FDA-approved drug for the treatment of pulmonary hypertension in newborns, and is extensively used in critical settings in the United States, Canada, Europe, Latin America and Asia. Ikaria has a staff of over 300 people and is headquartered in Clinton, N.J., with research facilities in Seattle and Madison, Wis., and manufacturing in Port Allen, La. For more information, please visit the company's Web site at

To view a related press release from the Fred Hutchinson Cancer Research Center, visit

For more information on the MacArthur Fellowship Program, visit tio n_Home.htm

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. UW computer scientists fighting computer virus "Cold War"
2. UW scientist, former WiCell director found stem cell company
3. Scientists find way to make human collagen in lab
4. Wisconsin scientists to be recognized for innovative biofuel technology
5. UW biophysical scientist honored as society fellow
6. UW scientist wins Pew grant to study little-known immune cells
7. UW-Madison scientists to mimic nature for newest cancer drugs
8. The Scientist magazine names Madison "hotspot" for biotechnology
9. UW scientists study strange material with communications potential
10. Scientists find nanotech method for examining cells
11. Scientist takes back patents and develops product others ignored
Post Your Comments:
(Date:12/1/2015)... -- Cepheid (Nasdaq: CPHD ) today announced that, ... Healthcare Conference in New York City ... outlook for the fourth quarter of 2015 and initiating ... term business model expectations. John Bishop , ... be the fastest growing company of the major market ...
(Date:12/1/2015)... 2015 ) ... U.K. Virology and Bacteriology Testing Market: Sales ... Supplier Shares by Test, Innovative Technologies, Competitive ... --> ) has announced ... and Bacteriology Testing Market: Sales and Volume ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global Stem Cells Group announced ... clinics in the cities of Arica and Iquique in northern Chile. The facilities are part ... offer the most advanced protocols and techniques in stem cell medicine to patients from around ...
(Date:11/30/2015)... 30, 2015  Culprits beware, a University at ... Jan Halámek, is taking crime scene fingerprint identification ...   -->   --> ... --> --> Halámek and ... a straightforward concept for identifying whether a culprit ...
Breaking Biology Technology:
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... 12, 2015  Arxspan has entered into an ... Harvard for use of its ArxLab cloud-based suite ... The partnership will support the institute,s efforts to ... research information internally and with external collaborators. The ... managing the Institute,s electronic laboratory notebook, compound and ...
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
Breaking Biology News(10 mins):